AB0390 Cardiovascular Morbidity and Associated Risk Factors in Spanish Patients with Chronic Inflammatory Rheumatic Diseases Attending Rheumatology Clinics: Baseline Data of the Carma Project

Objectives To establish the cardiovascular (CV) morbidity and associated risk factors for CV disease (CVD) in Spanish patients with chronic inflammatory rheumatic diseases (CIRD) and unexposed individuals attending rheumatology clinics Methods Analysis of data from the baseline visit of a 10-year prospective study (CARdiovascular in rheuMAtology-CARMA-project) that includes a cohort of patients with CIRD [rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA)] and another cohort of matched individuals without CIRD attending outpatient rheumatology clinics from sixty-seven hospitals in Spain. Prevalence of CV morbidity, CV risk factors and systematic coronary risk evaluation (SCORE) assessment were analyzed Results 2,234 patients (775 RA, 738 AS and 721 PsA) and 677 unexposed subjects were included. A high percentage of patients had low disease activity at the time of recruitment. PsA patients had more commonly classic CV risk factors and metabolic syndrome features than did the remaining individuals. Prevalence of CVD was higher in RA (10.5%) than in AS (7.6%), PsA (7.2%) and unexposed individuals (6.4%). A multivariate analysis adjusted for the presence of classic CV risk factors and disease duration revealed a positive trend for CVD in RA (OR=1.58; 95%CI=0.90-2.76; p=0.10) and AS (OR=1.77; 95%CI=0.96-3.27; p=0.07). Disease duration in all CIRD groups (RA: OR=1.06; 95%CI=1.01-1.11; AS: OR=1.06; 95%CI=1.01-1.06; PsA: OR=1.15; 95%CI=1.07-1.23) and functional capacity (HAQ) in RA (OR=2.15; 95%CI=1.29-3.56; p=0.003) were associated with an increased risk of CVD. Most patients had a moderate CV risk according to the SCORE charts. Conclusions Despite recent advances in the management of CIRD, prevalence of CVD remains increased in Spanish subjects with CIRD attending outpatient rheumatology clinics. Disclosure of Interest S. Castaneda: None declared, M. A. Martin Martinez: None declared, C. Gonzalez Juanatey: None declared, J. Llorca: None declared, M. J. Garcia Yebenes: None declared, S. Perez Vicente: None declared, J. T. Sanchez Costa: None declared, F. Diaz Gonzalez: None declared, M. A. Gonzalez Gay Grant/research support from: This project has been supported by an unrestricted grant from Abbvie, Spain. The design, analysis, interpretation of results and preparation of the manuscript has been done independently of Abbvie. Dr. Gonzalez-Gay9s studies have been supported by grants from “Fondo de Investigaciones Sanitarias” PI06/0024, PS09/00748 and PI12/00060, and RD12/0009/0013 (RIER) from “Instituto de Salud Carlos III” (ISCIII) (Spain).